Aktien Sensor

Recordati’s pharmaceutical company has made a breakthrough in rare disease treatment with its product ISTURISA, expanding its indication for treating Cushing’s syndrome.

Recordati Industria Chimica e Farmaceutica SpA has kicked off 2025 with strong revenue growth of 11.9% and increased adjusted net income, demonstrating resilience in the face of regional challenges.

Recordati Industria Chimica e Farmaceutica SpA has outlined a three-year growth plan (2025-2027) to drive organic growth, pursue strategic acquisitions, and maintain sector-leading margins.

Recordati Industria Chimica E Farmaceutica Spa’s Q3 2024 earnings call revealed a mixed picture, with fluctuating stock prices and valuation metrics suggesting potential upside for investors.